Table 1.
Characteristics of patients in the training and validation sets
| Training N = 950 | Validation N = 889 | |
|---|---|---|
| Age (years)* | 58.4 (13.1) | 57.5 (12.0) |
| Sex (female) | 944 (99.4%) | 886 (99.7%) |
| Tumor type | ||
| Lobular | 83 (8.7%) | 67 (7.6%) |
| Ductal | 797 (83.9%) | 783 (88.2%) |
| Other | 70 (7.4%) | 38 (4.3%) |
| Tumor grade | ||
| 1 | 275 (28.9%) | 226 (25.4%) |
| 2 | 465 (48.9%) | 424 (47.7%) |
| 3 | 210 (22.1%) | 239 (26.9%) |
| Tumor size (mm)** | 16.0 [11.0; 22.0] | 17.0 [12.0; 23.0] |
| Lymphovascular invasion | 185 (19.5%) | 231 (26.0%) |
| Estrogen receptors | 837 (88.1%) | 796 (89.5%) |
| Progesterone receptors | 767 (80.7%) | 720 (81.0%) |
| HER2 overexpression | 108 (11.4%) | 118 (13.3%) |
| ki67 (%)** | 15.0 [10.0; 25.0] | 15.0 [8.00; 30.0] |
| Risk Score** | 3.00 [2.00; 4.00] | 3.00 [2.00; 5.00] |
Data are summarized as n (%), mean (SD)*, or median [IQR]**, as appropriate